An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus
Phase of Trial: Phase III
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Adverse reactions; Registrational
- Sponsors Cara Therapeutics
- 07 Jan 2019 According to a Cara Therapeutics media release, the company has enrolled more than 200 patients. Thus far, over 100 patients have completed at least six months of treatment, with approximately 40 percent of these through the one-year treatment period.
- 14 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2019.
- 14 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2019.